Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nonmyeloablative Allogeneic Transplant (Mini-allo)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Scripps Health.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Jeffrey Andrey, MD, Scripps Health Identifier:
First received: January 6, 2011
Last updated: December 5, 2013
Last verified: December 2013
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.

Condition Intervention
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria
Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Waldenstrom Macroglobulinemia
Breast Cancer
Renal Cell Carcinoma
Ovarian Cancer
Procedure: Nonmyeloablative Allogeneic Transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation

Resource links provided by NLM:

Further study details as provided by Scripps Health:

Primary Outcome Measures:
  • Engraftment [ Time Frame: One year ]
    Evaluation of engraftment of donor stem cells by bone marrow examinations at days 30, 100, and 360 after transplant.

Secondary Outcome Measures:
  • Graft-versus-host disease [ Time Frame: One year ]
    Assess the incidence and severity of acute and/or chronic GVHD for patients transplanted on this protocol.

Estimated Enrollment: 50
Study Start Date: October 2001
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Cladribine + melphalan
Cladribine + melphalan conditioning
Procedure: Nonmyeloablative Allogeneic Transplant
Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
Total lymphoid irradiation conditioning
Procedure: Nonmyeloablative Allogeneic Transplant
Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)


Ages Eligible for Study:   18 Years to 72 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age > 55 years or
  2. Age < 55 and LVEF < 45% or creatinine clearance < 60 ml/min
  3. Ability to cover the cost of the transplant, necessary medications, and transportation/housing.
  4. Caregiver must be available while outpatient

Guidelines for Cladribine-Melphalan-based conditioning:

  • Bone Marrow Failure States Severe Aplastic Anemia (relapsed following immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic features or hemosiderosis)
  • AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second induction attempt)
  • ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse failing reinduction attempt)
  • CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd chronic or accelerated phase following gleevec therapy
  • Hodgkin's lymphoma (first or greater relapse)
  • Non-Hodgkin's Lymphoma
  • Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR Sensitive or refractory relapse
  • Indolent Histology Second or greater relapse
  • Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy)
  • Multiple Myeloma (10% residual plasmacytosis following anthracycline-based chemotherapy or residual disease following autologous transplant)
  • Waldenstrom Macroglobulinemia (must have failed either purine analogue-based chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias)

Guidelines for total lymphoid irradiation-based conditioning

  • MDS (RA, RARS)
  • CLL (Rai stage III or IV - must have received at least two different treatment regimens in the past)
  • Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy)
  • Renal Cell Cancer (metastatic disease at multiple sites)
  • Malignant Melanoma (metastatic disease at multiple sites)
  • Sarcoma (all subtypes presently, unresectable metastatic disease)
  • Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression within 6 months of initial platinum chemotherapy)
  • Thymoma (unresectable disease)

Exclusion Criteria:

  1. Prior allogeneic stem cell or bone marrow transplant
  2. Current or past history of invasive mycotic infection
  3. Breast Feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01272817

Contact: Carol Burian 858-554-2845

United States, California
Scripps Green Hospital Recruiting
La Jolla, California, United States, 92037
Contact: Cynthia Nelson, R.N.    858-554-2814   
Contact: Laurie Cobarrubia, R.N.    858-554-2853   
Principal Investigator: Jeffrey W. Andrey, M.D.         
Sub-Investigator: James R. Mason, M.D.         
Sub-Investigator: William E. Miller, M.D.         
Sponsors and Collaborators
Scripps Health
Principal Investigator: Jeffrey W. Andrey, M.D. Scripps Health
  More Information

Responsible Party: Jeffrey Andrey, MD, Director, Unrelated Donor Transplantation, Scripps Health Identifier: NCT01272817     History of Changes
Other Study ID Numbers: IRB#13-6255
Study First Received: January 6, 2011
Last Updated: December 5, 2013

Keywords provided by Scripps Health:
Nonmyeloablative transplant
Allogeneic transplant

Additional relevant MeSH terms:
Multiple Myeloma
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid
Myelodysplastic Syndromes
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Hodgkin Disease
Lymphoma, Mantle-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Carcinoma, Renal Cell
Leukemia, Myeloid, Acute
Waldenstrom Macroglobulinemia
Anemia, Aplastic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hemoglobinuria, Paroxysmal
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases processed this record on April 26, 2017